Last reviewed · How we verify
Infliximab (IFX alone)
Infliximab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.
Infliximab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | Infliximab (IFX alone) |
|---|---|
| Sponsor | Children's Memorial Health Institute, Poland |
| Drug class | TNF-α inhibitor (monoclonal antibody) |
| Target | TNF-α (Tumor Necrosis Factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Infliximab blocks TNF-α signaling by binding directly to soluble and membrane-bound TNF-α, preventing its interaction with TNF receptors on immune cells. This reduces the inflammatory cascade and immune activation in conditions driven by excessive TNF-α production. It is used to treat autoimmune and inflammatory diseases where TNF-α plays a central pathogenic role.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriasis
- Psoriatic arthritis
Common side effects
- Infections (including serious infections)
- Infusion reactions
- Headache
- Abdominal pain
- Nausea
- Tuberculosis reactivation
- Malignancy risk (long-term)
Key clinical trials
- Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
- InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease (PHASE3)
- A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis (PHASE4)
- The Use of Web-app Constant-Care in Patients With Acute Severe Ulcerative Colitis Treated With Rescue Therapy (NA)
- Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807) (PHASE3)
- Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422) (PHASE3)
- Managing Infliximab Reinduction After Temporary Discontinuation of Drug (PHASE3)
- Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |